Ikena Oncology (IKNA) 10-Q 15 May 23 2023 Q1 Quarterly report Financial data

Document and Entity Information

Document and Entity Information - shares	3 Months Ended
	Mar. 31, 2023	May 01, 2023
Cover [Abstract]
Document Type	10-Q
Amendment Flag	false
Document Period End Date	Mar. 31, 2023
Entity Registrant Name	IKENA ONCOLOGY, INC.
Entity Central Index Key	0001835579
Entity Incorporation, State or Country Code	DE
Entity File Number	001-40287
Entity Tax Identification Number	81-1697316
Entity Address, Address Line One	645 Summer Street
Entity Address, Address Line Two	Suite 101
Entity Address, City or Town	Boston
Entity Address, State or Province	MA
Entity Address, Postal Zip Code	02210
City Area Code	857
Local Phone Number	273-8343
Document Fiscal Year Focus	2023
Document Fiscal Period Focus	Q1
Entity Current Reporting Status	Yes
Current Fiscal Year End Date	--12-31
Entity Filer Category	Non-accelerated Filer
Entity Small Business	true
Entity Shell Company	false
Entity Interactive Data Current	Yes
Title of 12(b) Security	Common Stock, par value $0.001 per share
Trading Symbol	IKNA
Security Exchange Name	NASDAQ
Document Quarterly Report	true
Document Transition Report	false
Entity Emerging Growth Company	true
Entity Ex Transition Period	false
Entity Common Stock, Shares Outstanding		36,269,993

Condensed Consolidated Balance

Condensed Consolidated Balance Sheets - USD ($) $ in Thousands	Mar. 31, 2023	Dec. 31, 2022
Current assets:
Cash and cash equivalents	$ 29,329	$ 59,919
Marketable securities	108,484	97,028
Prepaid expenses and other current assets	3,365	3,063
Total current assets	141,178	160,010
Property and equipment, net	3,126	3,205
Right-of-use asset	4,918	5,255
Deposits and other assets	3,179	3,789
Total assets	152,401	172,259
Current liabilities:
Accounts payable	2,759	2,093
Accrued expenses and other current liabilities	5,424	8,343
Operating lease liability	1,920	1,907
Deferred revenue	3,847	9,160
Total current liabilities	13,950	21,503
Long-term portion of operating lease liability	3,429	3,787
Total liabilities	17,379	25,290
Commitments and contingencies (Note 12)
Stockholders equity
Preferred Stock, $0.001 par value - 10,000,000 shares authorized as of March 31, 2023 and December 31, 2022; No shares issued and outstanding as of March 31, 2023 or December 31, 2022
Common stock, $0.001 par value - 150,000,000 shares authorized, as of March 31, 2023 and December 31, 2022; 36,257,493 issued and outstanding as of March 31, 2023 and December 31, 2022	36	36
Additional paid-in capital	363,915	361,915
Accumulated other comprehensive loss	(491)	(763)
Accumulated deficit	(228,438)	(214,219)
Total stockholders' equity	135,022	146,969
Total liabilities and stockholders' equity	$ 152,401	$ 172,259

Condensed Consolidated Balanc_2

Condensed Consolidated Balance Sheets (Parenthetical) - $ / shares	Mar. 31, 2023	Dec. 31, 2022
Statement of Financial Position [Abstract]
Preferred stock, par value	$ 0.001	$ 0.001
Preferred stock, shares authorized	10,000,000	10,000,000
Preferred stock, shares issued	0	0
Preferred stock, shares outstanding	0	0
Common stock, par value	$ 0.001	$ 0.001
Common stock, shares authorized	150,000,000	150,000,000
Common stock, shares issued	36,257,493	36,257,493
Common stock, shares outstanding	36,257,493	36,257,493

Condensed Consolidated Statemen

Condensed Consolidated Statements of Operations and Comprehensive Loss - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2023	Mar. 31, 2022
Research and development revenue under collaboration agreement	$ 5,313	$ 3,384
Revenue from Contract with Customer, Product and Service [Extensible List]	us-gaap:InProcessResearchAndDevelopmentMember	us-gaap:InProcessResearchAndDevelopmentMember
Operating expenses:
Research and development	$ 15,552	$ 14,343
General and administrative	5,276	6,003
Total operating expenses	20,828	20,346
Loss from operations	(15,515)	(16,962)
Other income (expense):
Interest income	730	172
Other income (expense)	566	(49)
Total other income, net	1,296	123
Net loss	(14,219)	(16,839)
Other comprehensive loss:
Unrealized gain (loss) on marketable securities	272	(478)
Total comprehensive loss	$ (13,947)	$ (17,317)
Net loss per share:
Net loss per share attributable to common stockholders basic	$ (0.39)	$ (0.47)
Net loss per share attributable to common stockholders diluted	$ (0.39)	$ (0.47)
Weighted-average common stock outstanding, basic	36,257,493	36,075,407
Weighted-average common stock outstanding, diluted	36,257,493	36,075,407

Condensed Consolidated Statem_2

Condensed Consolidated Statements of Stockholders' Equity - USD ($) $ in Thousands	Total	Common Stock	Additional Paid-in Capital	Accumulated Other Comprehensive Loss	Accumulated Deficit
Beginning Balance, Shares at Dec. 31, 2021		35,975,034
Beginning Balance at Dec. 31, 2021	$ 207,877	$ 36	$ 353,295		$ (145,454)
Stock-based compensation	1,900		1,900
Exercise of stock options	495		495
Exercise of stock options, Shares		134,500
Other comprehensive income (loss)	(478)			$ (478)
Net loss	(16,839)				(16,839)
Ending Balance, Shares at Mar. 31, 2022		36,109,534
Ending Balance at Mar. 31, 2022	192,955	$ 36	355,690	(478)	(162,293)
Beginning Balance, Shares at Dec. 31, 2022		36,257,493
Beginning Balance at Dec. 31, 2022	146,969	$ 36	361,915	(763)	(214,219)
Stock-based compensation	$ 2,000		2,000
Exercise of stock options, Shares	0
Other comprehensive income (loss)	$ 272			272
Net loss	(14,219)				(14,219)
Ending Balance, Shares at Mar. 31, 2023		36,257,493
Ending Balance at Mar. 31, 2023	$ 135,022	$ 36	$ 363,915	$ (491)	$ (228,438)

Condensed Consolidated Statem_3

Condensed Consolidated Statements of Cash Flows - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2023	Mar. 31, 2022
Cash flows from operating activities
Net loss	$ (14,219)	$ (16,839)
Adjustments to reconcile net loss to net cash used in operating activities
Depreciation	231	180
Amortization of premiums and discounts on marketable securities	(530)	42
Stock-based compensation	2,000	1,900
Non-cash operating lease expense	337	312
Changes in operating assets and liabilities:
Prepaid expenses and other current assets	308	624
Accounts payable	666	4
Accrued expenses and other current liabilities	(2,919)	(1,523)
Lease liability	(345)	(307)
Deferred revenue	(5,313)	(3,384)
Deposits and other assets		(793)
Net cash flows used in operating activities	(19,784)	(19,784)
Cash flows from investing activities
Purchases of property and equipment	(152)	(33)
Purchase of marketable securities	(41,726)	(166,018)
Sales and maturities of marketable securities	31,072
Net cash flows used in investing activities	(10,806)	(166,051)
Cash flows from financing activities
Proceeds from exercise of stock options		495
Net cash flows provided by financing activities		495
Net increase (decrease) in cash and cash equivalents and restricted cash	(30,590)	(185,340)
Cash, cash equivalents and restricted cash, beginning of period	60,791	233,089
Cash, cash equivalents and restricted cash, end of period	30,201	47,749
Cash and cash equivalents	29,329	46,877
Restricted cash included in other assets	872	872
Cash, cash equivalents and restricted cash, end of period	30,201	47,749
Supplemental cash flow information
Reclassification of deposits and other assets to prepaid expenses and other current assets	609,866
Noncash investing and financing activities
Unrealized gains (losses) on marketable securities	$ 272	$ (478)

Organization and Basis of Prese

Organization and Basis of Presentation	3 Months Ended
	Mar. 31, 2023
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Organization and Basis of Presentation	1. Organization and Basis of Presentation Ikena Oncology Inc. (the “Company”) is a targeted oncology company, focused on developing differentiated therapies for patients in need that target nodes of cancer growth, spread, and therapeutic resistance in the Hippo and RAS onco-signaling network. The Company’s lead targeted oncology program, IK-930, is a TEAD1-selective Hippo pathway inhibitor, a known tumor suppressor pathway that also drives resistance to multiple targeted therapies. The Company’s first program in the RAS pathways, IK-595, is designed to trap MEK and RAF in an inactive complex, more completely inhibiting RAS signals than existing inhibitors. In addition, the Company is developing IK-175, an aryl hydrocarbon receptor (“AHR”) antagonist in collaboration with Bristol-Myers Squibb Company (“Bristol-Myers Squibb”). The Company’s focus on patient-driven development allows it to research both known and novel targets, with a shared guiding principle of aiming to address the unmet needs of biomarker-defined patient populations. Since the Company commenced operations in 2016, it has advanced multiple product candidates into clinical development. In addition, the Company has a robust discovery engine and portfolio of early stage targeted oncology programs. Across the entirety of its pipeline, the Company aims to utilize its depth of institutional knowledge and breadth of tools to efficiently develop the right drug using the right modality for the right patient. Basis of Presentation: The Company’s condensed consolidated financial statements have been prepared in conformity with accounting principles generally accepted in the United States of America (“U.S. GAAP”) for interim financial reporting. Any reference in these notes to applicable guidance is meant to refer to the authoritative U.S. GAAP as found in the ASC and Accounting Standards Update (“ASU”) of the Financial Accounting Standards Board (“FASB”). The accompanying condensed consolidated financial statements and footnotes to the financial statements have been prepared on the same basis as the most recently audited annual financial statements and, in the opinion of management, reflect all normal recurring adjustments necessary for the fair presentation of the Company’s financial position for the reported periods. The results of operations for any interim periods are not necessarily indicative of results to be expected for the year ending December 31, 2023 , any other interim periods, or any future year or period. These condensed consolidated financial statements should be read in conjunction with, the Company’s audited consolidated financial statements for the year ended December 31, 2022, which were included in its Annual Report on Form 10-K that was filed with the Securities and Exchange Commission (“SEC”) on March 14, 2023.

Summary of Significant Accounti

Summary of Significant Accounting Policies	3 Months Ended
	Mar. 31, 2023
Accounting Policies [Abstract]
Summary of Significant Accounting Policies	2. Summary of Significant Accounting Policies Principles of Consolidation: The accompanying consolidated financial statements include the accounts of the Company and its wholly-owned subsidiaries, Arrys Therapeutics, Inc. (“Arrys”), Ikena Oncology Securities Corporation, and Amplify Medicines, Inc, (“Amplify”). All intercompany balances and transactions have been eliminated in consolidation. Use of Estimates: The preparation of the Company’s financial statements requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenue and expenses during the reporting period. Estimates and judgments are based on historical information and other market-specific or various relevant assumptions, including in certain circumstances, future projections, that management believes to be reasonable under the circumstances. Actual results could differ materially from estimates. Significant estimates and assumptions are used for, but not limited to the accruals for research and development expenses and research and development revenue under a collaboration agreement. Summary of Significant Accounting Policies: The significant accounting policies and estimates used in the preparation of the accompanying consolidated financial statements are described in the Company’s audited consolidated financial statements for the year ended December 31, 2022 included in the Company’s Annual Report on Form 10-K that was filed with the SEC on March 14, 2023. There have been no material changes in the Company’s significant accounting policies during the three months ended March 31, 2023 except as discussed below. Concentration of Credit Risk and of Significant Suppliers: Financial instruments that potentially subject the Company to concentrations of credit risk consist principally of cash, cash equivalents, and marketable securities. Cash and cash equivalents are deposited with federally insured financial institutions in the United States and may, at times, exceed federally insured limits. The Company places marketable securities with a highly rated financial institution. Additionally, as of March 31, 2023, the Company has not experienced any credit related losses on accounts that hold the Company’s cash, cash equivalents and marketable securities. The Company is dependent on third-party manufacturers and clinical research organizations (“CROs”) to supply products and provide services for research and development activities in its programs. In particular, the Company relies and expects to continue to rely on a small number of manufacturers to supply it with its requirements for the active pharmaceutical ingredients and formulated drugs related to these programs. The Company also relies on at least two CROs to conduct its clinical trials. The Company’s programs could be adversely affected if a third-party manufacturer or a CRO is unable to successfully carry out their contractual obligations or meet expected deadlines. If a third-party manufacturer or a CRO needs to be replaced, the Company may not be able to complete its program development on its anticipated timelines and may incur additional expenses as a result, which could be significant. Recent Accounting Pronouncements: From time to time, new accounting pronouncements are issued by the FASB or other standard setting bodies and adopted by us as of the specified effective date. Unless otherwise discussed, the Company believes that the impact of recently issued standards that are not yet effective will not have a material impact on our consolidated financial statements and disclosures.

Fair Value Measurements

Fair Value Measurements	3 Months Ended
	Mar. 31, 2023
Fair Value Disclosures [Abstract]
Fair Value Measurements	3. Fair Value Measurements The following table presents information about the Company’s financial assets measured or disclosed at fair value by level within the fair value hierarchy (in thousands): As of March 31, Quoted Prices in Active Markets Significant Observable Inputs Significant Unobservable Inputs Assets Cash equivalents: Money market funds $ 11,613 $ 11,613 $ — $ — Corporate debt securities 3,496 — 3,496 — U.S. treasury securities 10,936 — 10,936 — Marketable securities U.S. treasury securities 48,885 — 48,885 — Corporate debt securities 59,599 — 59,599 — Total assets $ 134,529 $ 11,613 $ 122,916 $ — As of December 31, Quoted Prices in Active Markets Significant Observable Inputs Significant Unobservable Inputs Assets Cash equivalents: Money market funds $ 55,861 $ 55,861 $ — $ — Marketable securities U.S. treasury securities 22,606 — 22,606 — Corporate debt securities 74,422 — 74,422 — Total assets $ 152,889 $ 55,861 $ 97,028 $ — During the three months ended March 31, 2023 and twelve months ended December 31, 2022 , there were no transfers into or out of Level 3.

Marketable Securities

Marketable Securities	3 Months Ended
	Mar. 31, 2023
Investments, Debt and Equity Securities [Abstract]
Marketable Securities	4. Marketable securities The following table summarizes the Company's marketable securities (in thousands): As of March 31, 2023 Amortized Cost Gross Unrealized Gains Gross Unrealized Losses Fair Value U.S. treasury securities $ 59,845 $ 4 $ ( 28 ) $ 59,821 Corporate debt securities 63,562 1 ( 468 ) 63,095 Total $ 123,407 $ 5 $ ( 496 ) $ 122,916 December 31, 2022 Amortized Cost Gross Unrealized Gains Gross Unrealized Losses Fair Value U.S. treasury securities $ 22,630 $ — $ ( 24 ) $ 22,606 Corporate debt securities 75,161 — ( 739 ) 74,422 Total $ 97,791 $ — $ ( 763 ) $ 97,028 In accordance with the Company's investment policy, it places investments in investment grade securities with high credit quality issuers, and generally limits the amount of credit exposure to any one issuer. The Company evaluates securities for impairment at the end of each reporting period. Factors considered include whether a decline in fair value below the amortized cost basis is due to credit-related factors or non-credit-related factors, the financial condition and near-term prospects of the issuer, and the Company’s intent and ability to hold the investment to allow for an anticipated recovery in fair value. As of March 31, 2023 , the Company held 37 marketable securities in an unrealized loss position. The Company does not intend to sell its marketable securities and it is not more likely than not that the Company will be required to sell the investments before the recovery of their amortized cost bases, which may be maturity. The Company also believes that it will be able to collect both principal and interest amounts due at maturity. The Company did no t record any impairment charges related to its available-for-sale securities during the three months ended March 31, 2023 and 2022 . The Company did no t recognize any credit-related allowance to available-for-sale securities as of the three months ended March 31, 2023 and 2022. The fair values of the Company's marketable securities by classification in the condensed consolidated balance sheets were as follows: As of March 31, 2023 As of December 31, Cash and cash equivalents $ 14,432 $ — Marketable securities 108,484 97,028 Total $ 122,916 $ 97,028 Marketable securities fair value by contractual maturity were as follows (in thousands): As of As of Due in one year or less $ 111,617 $ 79,652 Due after one year through five years 11,299 17,376 Total $ 122,916 $ 97,028

Prepaid Expenses and Other Curr

Prepaid Expenses and Other Current Assets	3 Months Ended
	Mar. 31, 2023
Prepaid Expense and Other Assets, Current [Abstract]
Prepaid Expenses and Other Current Assets	5. Prepaid Expenses and Other Current Assets Prepaid expenses and other current assets consist of the following (in thousands): As of March 31, 2023 As of December 31, 2022 Clinical, manufacturing and scientific development $ 1,862 $ 1,372 Prepaid Insurance 90 727 Other 1,413 964 Total $ 3,365 $ 3,063

Property and Equipment, Net

Property and Equipment, Net	3 Months Ended
	Mar. 31, 2023
Property, Plant and Equipment [Abstract]
Property and Equipment, Net	6. Property and Equipment, net Property and equipment, net consist of the following (in thousands): As of March 31, 2023 As of December 31, 2022 Property and equipment: Lab equipment $ 3,007 $ 2,858 Leasehold improvements 1,219 1,216 Electronic equipment and software 481 481 Furniture and fixtures 475 475 Total property and equipment 5,182 5,030 Less: accumulated depreciation ( 2,056 ) ( 1,825 ) Property and equipment, net $ 3,126 $ 3,205 Depreciation expense for each of the three months ended March 31, 2023 and 2022 was $ 0.2 million . There were no impairments for the three months ended March 31, 2023 and 2022 .

Accrued Expenses and Other Curr

Accrued Expenses and Other Current Liabilities	3 Months Ended
	Mar. 31, 2023
Accrued Expenses And Other Current Liabilities [Abstract]
Accrued Expenses and Other Current Liabilities	7. Accrued Expenses and Other Current Liabilities Accrued expenses and other current liabilities consist of the following (in thousands): As of March 31, 2023 As of December 31, 2022 Employee compensation $ 1,128 $ 3,236 Research and development expenses 3,545 4,462 Professional fees 737 526 Other current liabilities 14 119 Total $ 5,424 $ 8,343

Collaboration Agreement and Sto

Collaboration Agreement and Stock Purchase Agreement with Bristol Myers Squibb	3 Months Ended
	Mar. 31, 2023
Collaboration And Stock Purchase Agreement [Abstract]
Collaboration Agreement and Stock Purchase Agreement with Bristol Myers Squibb	8. Collaboration Agreement and Stock Purchase Agreement with Bristol-Myers Squibb In January 2019, the Company entered into the Bristol-Myers Squibb Collaboration Agreement with Celgene Corporation, which was acquired by Bristol-Myers Squibb in November 2019, whereby the Company will carry out initial research and development activities with the goal of identifying and developing drug candidates for certain cancer types. Concurrent with execution of the Bristol-Myers Squibb Collaboration Agreement, the Company entered into a stock purchase agreement with Bristol-Myers Squibb, which resulted in the issuance of 14,545,450 shares of Series A-1 Preferred Stock (the “Stock Purchase Agreement”). In connection with the Company’s initial public offering (“IPO”), the series A-1 preferred stock converted into common stock. Agreement Structure Under the Bristol-Myers Squibb Collaboration Agreement, the Company will conduct exploratory and discovery activities, with the goal of identifying product candidates for certain targets, which are in the kynurenine pathway, which the Company is developing as IK-412, and the AHR, which the Company is developing as IK-175. The Company is obligated to advance research and development activities through the earlier of January 2024 or the completion of a Phase 1b clinical trial for each program (“the research term”). Bristol-Myers Squibb has the option to receive a global-development, manufacture and commercialization license for the product candidate, which expires in January 2024. Subsequent to the delivery of a license, Bristol-Myers Squibb is responsible for the worldwide development, manufacturing and commercialization of these product candidates. Bristol-Myers Squibb paid the Company a total of $ 95.0 million in aggregate upfront consideration related to the Bristol-Myers Squibb Collaboration Agreement and Stock Purchase Agreement. The Company is eligible to receive $ 50.0 million, in case of an exercise of its option with respect to IK-175, and $ 40.0 million, in case of an exercise of its option with respect to IK-412. If the Company does not complete a Phase 1b clinical trial by the end of the research term, the Company may provide a data package to Bristol-Myers Squibb to support the decision to exercise the option for an additional $ 0.25 million. Upon the exercise of the delivery of each license, the Company becomes eligible to receive up to $ 450 million in milestone payments as well as a tiered royalty on worldwide sales from the high single to low teen digits. Accounting Considerations of the Agreement The Bristol-Myers Squibb Collaboration Agreement and the Stock Purchase Agreement were executed concurrently and in contemplation of each other. The issuance of Series A-1 Preferred Stock was initially accounted for at fair value. The purchase price for the Series A-1 Preferred Stock was considered to be at a discount from fair value, and therefore $ 1.8 million of the upfront from the Bristol-Myers Squibb Collaboration Agreement was allocated to the equity arrangement. The Company determined that the Bristol-Myers Squibb Collaboration Agreement represented a contract with a customer and should be accounted for in accordance with ASC 606. The Company identified the two performance obligations, which are research and development services for IK-175 and IK-412. The options to receive worldwide development and commercialization licenses for the two targets and the option to receive manufacturing services in the future were determined to not provide any material rights to the customer and are therefore not considered to be performance obligations. The arrangement also contains certain other items, including participation on joint oversight committees. The Company identified $ 78.7 million of total transaction price which represents the upfront consideration allocated to the revenue arrangement. Additional consideration to be paid to the Company upon exercise of a right to receive a license or potential milestone and royalty payments are excluded from the transaction price as they relate to amounts that can only be achieved subsequent to the exercise of an options and are outside of the initial contact term. Based on the distinct performance obligations identified above, the Company allocated the $ 78.7 million transaction price based on relative estimated standalone selling prices of each of its performance obligations as follows: • $ 41.2 million for research and development services for IK-175; and • $ 37.5 million for research and development services for IK-412. The Company determined the estimated standalone selling price for the research and development services based on internal estimates of the costs to perform the services, including expected internal expenses and expenses with third parties, adjusted to include a reasonable profit margin. Significant inputs used to determine the total expense of the research and development activities include the length of time required and the number and cost of various studies that will be performed to complete the applicable development plan. The Company is recognizing revenue related to each of its performance obligations as the research and development services are performed through January 2024. The Company recognizes revenue related to research and development services performed using an input method by calculating costs incurred at each period end relative to total costs expected to be incurred. In December 2021, the Company re-assessed the IK-412 program, which experienced manufacturing delays as a key component required in the manufacturing of IK-412, is similarly essential to the manufacturing of COVID-19 vaccines and therapies. As such, the availability of the component was delayed as resources were allocated towards vaccine production. Considering these delays and the timeline of the Bristol-Myers Squibb partnership, the Company made the strategic decision to pause IK-412 development activities for the remainder of the Bristol-Myers Squibb research term outside of the committed manufacturing efforts, which were completed in 2022. The Company recognized revenue of $ 5.3 million and $ 3.4 million in the three months ended March 31, 2023 and 2022, respectively, from the Bristol-Myers Squibb Collaboration Agreement, that in each case was previously included in deferred revenue at the beginning of the respective period. The condensed consolidated balance sheet as of March 31, 2023 includes current deferred revenue of $ 3.8 million related to this agreement. This amount is expected to be recognized as performance obligations are satisfied through the completion of the research and development services for the partnered programs.

Stock-Based Compensation

Stock-Based Compensation	3 Months Ended
	Mar. 31, 2023
Share-Based Payment Arrangement [Abstract]
Stock-Based Compensation	9. Stock-Based Compensation The Company grants stock options under the 2021 Stock Incentive Plan (the “2021 Plan”). The Company also has stock options outstanding under the 2016 Stock Incentive Plan (“2016 Plan”), but is no longer granting awards under such plan. All shares of common stock underlying any awards that are forfeited, cancelled, expired, repurchased, or otherwise terminated under the 2021 and 2016 Plans are added back to the shares of common stock available for issuance under the 2021 Plan. On January 1, 2023 the number of shares available for issuance under the 2021 Plan increased by 1,450,299 shares as a result of the evergreen provision. As of March 31, 2023 , 3,033,386 shares of common stock remain available for future issuance under the 2021 Plan. The total compensation expense recognized in the statements of operations associated with all the stock-based compensation awards granted by the Company is as follows (in thousands): Three Months Ended March 31, 2023 2022 Research and development $ 1,072 $ 997 General and administrative 928 903 Total $ 2,000 $ 1,900 The weighted-average fair value of the stock options granted during the three months ended March 31, 2023 was $ 1.96 . As of March 31, 2023, the total unrecognized stock-based compensation expense for unvested options was $ 17.8 million which is expected to be recognized over a weighted average period of 2.7 years. The following table summarizes stock option activity under the 2021 Plan for the three months ended March 31, 2023: Number of Weighted- Weighted- Aggregate Outstanding as of December 31, 2022 6,589,479 $ 7.29 7.73 $ 362 Granted 1,370,975 2.63 Exercised — — Cancelled or forfeited ( 314,147 ) 5.71 Outstanding as of March 31, 2023 7,646,307 $ 6.52 7.95 $ 2,037 Vested or expected to vest as of March 31, 2023 7,646,307 $ 6.52 7.95 $ 2,037 Options exercisable as of March 31, 2023 3,311,203 $ 6.32 6.65 $ 892 No options were exercised during the three months ended March 31, 2023. The aggregate intrinsic value of options exercised for the three months ended March 31, 2022 was $ 0.9 million . The fair value of each option award granted is estimated on the date of grant using the Black-Scholes option pric ing model and the weighted average assumptions. The underlying assumptions used to value stock options granted to participants using the Black-Scholes option-pricing presented on a weight average basis were as follows: Three Months Ended March 31, 2023 2022 Risk-free interest rate 3.92 % 1.67 % Expected dividend yield 0 % 0 % Expected option term (in years) range 6.08 6.07 Expected stock price volatility 86.45 83.55 Employee Stock Purchase Plan On March 20, 2021, the Company’s stockholders approved the 2021 Employee Stock Purchase Plan (the “ESPP”), which became effective on March 30, 2021 . The ESPP initially provides participating employees with the opportunity to purchase up to an aggregate of 346,613 shares of the Company’s common stock. An annual increase in the number of shares of common stock reserved and available for issuance under the ESPP shall be equal to 1 % of the number of shares of common stock outstanding on the immediately preceding December 31; and such lesser number of shares as determined by the Administrator as provided in the ESPP. As of March 31, 2023 , there has been no increase in the shares reserved and available for issuance and no shares have been purchased by employees under the ESPP.

Research License Agreements

Research License Agreements	3 Months Ended
	Mar. 31, 2023
Research and Development [Abstract]
Research License Agreements	10. Research License Agreements During 2015, the Company entered into an exclusive patent license agreement (the “UT Austin License”) to license certain technologies and intellectual property rights from the University of Texas at Austin (the “University”), an entity affiliated with a director of the Company at the time of the agreement. The UT Austin License shall remain in effect until the expiration or abandonment of the last to expire technologies and intellectual property rights. The Company shall pay License Maintenance fees annually of $ 40 thousand. Additionally, the Company shall make additional milestone payments to the University upon meeting certain development milestones in the aggregate of $ 4.7 million upon meeting certain development milestones during the term of the UT Austin License. The Company will pay the University royalties as defined in the UT Austin License on any commercialized product sales related to the licensed technology in a percentage in the low single digits. The Company will also be responsible for reimbursing the University for certain patent-related costs incurred on its behalf. In 2018, the Company acquired IPR&D on an Arrys’ immune-oncology candidate based on the intellectual property associated with Arrys’ AskAt License as part of the acquisition of Arrys. Total consideration allocated to the technology was $ 28.5 million and was recognized as research and development expense upon the acquisition. The AskAt License is intended to be used by the Company in its future development of therapeutic drug candidates for eventual clinical development and commercialization. The Company shall make additional milestone payments to AskAt upon meeting certain development milestones totaling $ 4 million, as well as certain sales event milestones ranging from $ 50 million to $ 250 million contingent on sales in a calendar year, during the term of the AskAt License. The Company will pay the AskAt royalties a percentage in the low single digits as defined in the AskAt License on any commercialized product sales related to the licensed technology.

Commitments and Contingencies

Commitments and Contingencies	3 Months Ended
	Mar. 31, 2023
Commitments and Contingencies Disclosure [Abstract]
Commitments and Contingencies	11. Commitments and Contingencies The Company is also party to various agreements, principally relating to licensed technology, that require future payments relating to milestones not met as of March 31, 2023 or royalties on future sales of specified products that have not yet occurred as of March 31, 2023 .

Net Loss per Share Attributable

Net Loss per Share Attributable to Common Stockholders	3 Months Ended
	Mar. 31, 2023
Earnings Per Share [Abstract]
Net Loss per Share Attributable to Common Stockholders	12. Net Loss per Share Attributable to Common Stockholders The Company has generated a net loss in all periods presented, therefore the basic and diluted net loss per share attributable to common stockholders are the same as the inclusion of the potentially dilutive securities would be anti-dilutive. The following table sets forth the outstanding potentially dilutive securities that have been excluded in the calculation of diluted net loss per share because to do so would be anti-dilutive: Three Months Ended March 31, 2023 2022 Options to purchase Common Stock 7,646,307 6,270,759 Total 7,646,307 6,270,759

Summary of Significant Accoun_2

Summary of Significant Accounting Policies (Policies)	3 Months Ended
	Mar. 31, 2023
Accounting Policies [Abstract]
Principles of Consolidation	Principles of Consolidation: The accompanying consolidated financial statements include the accounts of the Company and its wholly-owned subsidiaries, Arrys Therapeutics, Inc. (“Arrys”), Ikena Oncology Securities Corporation, and Amplify Medicines, Inc, (“Amplify”). All intercompany balances and transactions have been eliminated in consolidation.
Use of Estimates	Use of Estimates: The preparation of the Company’s financial statements requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenue and expenses during the reporting period. Estimates and judgments are based on historical information and other market-specific or various relevant assumptions, including in certain circumstances, future projections, that management believes to be reasonable under the circumstances. Actual results could differ materially from estimates. Significant estimates and assumptions are used for, but not limited to the accruals for research and development expenses and research and development revenue under a collaboration agreement.
Summary of Significant Accounting Policies	Summary of Significant Accounting Policies: The significant accounting policies and estimates used in the preparation of the accompanying consolidated financial statements are described in the Company’s audited consolidated financial statements for the year ended December 31, 2022 included in the Company’s Annual Report on Form 10-K that was filed with the SEC on March 14, 2023. There have been no material changes in the Company’s significant accounting policies during the three months ended March 31, 2023 except as discussed below.
Concentration of Credit Risk and of Significant Suppliers	Concentration of Credit Risk and of Significant Suppliers: Financial instruments that potentially subject the Company to concentrations of credit risk consist principally of cash, cash equivalents, and marketable securities. Cash and cash equivalents are deposited with federally insured financial institutions in the United States and may, at times, exceed federally insured limits. The Company places marketable securities with a highly rated financial institution. Additionally, as of March 31, 2023, the Company has not experienced any credit related losses on accounts that hold the Company’s cash, cash equivalents and marketable securities. The Company is dependent on third-party manufacturers and clinical research organizations (“CROs”) to supply products and provide services for research and development activities in its programs. In particular, the Company relies and expects to continue to rely on a small number of manufacturers to supply it with its requirements for the active pharmaceutical ingredients and formulated drugs related to these programs. The Company also relies on at least two CROs to conduct its clinical trials. The Company’s programs could be adversely affected if a third-party manufacturer or a CRO is unable to successfully carry out their contractual obligations or meet expected deadlines. If a third-party manufacturer or a CRO needs to be replaced, the Company may not be able to complete its program development on its anticipated timelines and may incur additional expenses as a result, which could be significant.
Recent Accounting Pronouncements	Recent Accounting Pronouncements: From time to time, new accounting pronouncements are issued by the FASB or other standard setting bodies and adopted by us as of the specified effective date. Unless otherwise discussed, the Company believes that the impact of recently issued standards that are not yet effective will not have a material impact on our consolidated financial statements and disclosures.

Fair Value Measurements (Tables

Fair Value Measurements (Tables)	3 Months Ended
	Mar. 31, 2023
Fair Value Disclosures [Abstract]
Summary of Financial Assets Measured at Fair Value	The following table presents information about the Company’s financial assets measured or disclosed at fair value by level within the fair value hierarchy (in thousands): As of March 31, Quoted Prices in Active Markets Significant Observable Inputs Significant Unobservable Inputs Assets Cash equivalents: Money market funds $ 11,613 $ 11,613 $ — $ — Corporate debt securities 3,496 — 3,496 — U.S. treasury securities 10,936 — 10,936 — Marketable securities U.S. treasury securities 48,885 — 48,885 — Corporate debt securities 59,599 — 59,599 — Total assets $ 134,529 $ 11,613 $ 122,916 $ — As of December 31, Quoted Prices in Active Markets Significant Observable Inputs Significant Unobservable Inputs Assets Cash equivalents: Money market funds $ 55,861 $ 55,861 $ — $ — Marketable securities U.S. treasury securities 22,606 — 22,606 — Corporate debt securities 74,422 — 74,422 — Total assets $ 152,889 $ 55,861 $ 97,028 $ —

Marketable Securities (Tables)

Marketable Securities (Tables)	3 Months Ended
	Mar. 31, 2023
Investments, Debt and Equity Securities [Abstract]
Marketable Securities	The following table summarizes the Company's marketable securities (in thousands): As of March 31, 2023 Amortized Cost Gross Unrealized Gains Gross Unrealized Losses Fair Value U.S. treasury securities $ 59,845 $ 4 $ ( 28 ) $ 59,821 Corporate debt securities 63,562 1 ( 468 ) 63,095 Total $ 123,407 $ 5 $ ( 496 ) $ 122,916 December 31, 2022 Amortized Cost Gross Unrealized Gains Gross Unrealized Losses Fair Value U.S. treasury securities $ 22,630 $ — $ ( 24 ) $ 22,606 Corporate debt securities 75,161 — ( 739 ) 74,422 Total $ 97,791 $ — $ ( 763 ) $ 97,028
Summary Of Fair Values Of Marketable Securities	The fair values of the Company's marketable securities by classification in the condensed consolidated balance sheets were as follows: As of March 31, 2023 As of December 31, Cash and cash equivalents $ 14,432 $ — Marketable securities 108,484 97,028 Total $ 122,916 $ 97,028
Schedule of Marketable Securities Fair Value By Contractual Maturity	Marketable securities fair value by contractual maturity were as follows (in thousands): As of As of Due in one year or less $ 111,617 $ 79,652 Due after one year through five years 11,299 17,376 Total $ 122,916 $ 97,028

Prepaid Expenses and Other Cu_2

Prepaid Expenses and Other Current Assets (Tables)	3 Months Ended
	Mar. 31, 2023
Prepaid Expense and Other Assets, Current [Abstract]
Prepaid Expenses and Other Current Assets	Prepaid expenses and other current assets consist of the following (in thousands): As of March 31, 2023 As of December 31, 2022 Clinical, manufacturing and scientific development $ 1,862 $ 1,372 Prepaid Insurance 90 727 Other 1,413 964 Total $ 3,365 $ 3,063

Property and Equipment, Net (Ta

Property and Equipment, Net (Tables)	3 Months Ended
	Mar. 31, 2023
Property, Plant and Equipment [Abstract]
Summary of Property and Equipment, Net	Property and equipment, net consist of the following (in thousands): As of March 31, 2023 As of December 31, 2022 Property and equipment: Lab equipment $ 3,007 $ 2,858 Leasehold improvements 1,219 1,216 Electronic equipment and software 481 481 Furniture and fixtures 475 475 Total property and equipment 5,182 5,030 Less: accumulated depreciation ( 2,056 ) ( 1,825 ) Property and equipment, net $ 3,126 $ 3,205

Accrued Expenses and Other Cu_2

Accrued Expenses and Other Current Liabilities (Tables)	3 Months Ended
	Mar. 31, 2023
Accrued Expenses And Other Current Liabilities [Abstract]
Summary of Accrued Expenses and Other Current Liabilities	Accrued expenses and other current liabilities consist of the following (in thousands): As of March 31, 2023 As of December 31, 2022 Employee compensation $ 1,128 $ 3,236 Research and development expenses 3,545 4,462 Professional fees 737 526 Other current liabilities 14 119 Total $ 5,424 $ 8,343

Stock-Based Compensation (Table

Stock-Based Compensation (Tables)	3 Months Ended
	Mar. 31, 2023
Share-Based Payment Arrangement [Abstract]
Schedule of Total Compensation Expense	The total compensation expense recognized in the statements of operations associated with all the stock-based compensation awards granted by the Company is as follows (in thousands): Three Months Ended March 31, 2023 2022 Research and development $ 1,072 $ 997 General and administrative 928 903 Total $ 2,000 $ 1,900
Summary of Stock Option Activity	The following table summarizes stock option activity under the 2021 Plan for the three months ended March 31, 2023: Number of Weighted- Weighted- Aggregate Outstanding as of December 31, 2022 6,589,479 $ 7.29 7.73 $ 362 Granted 1,370,975 2.63 Exercised — — Cancelled or forfeited ( 314,147 ) 5.71 Outstanding as of March 31, 2023 7,646,307 $ 6.52 7.95 $ 2,037 Vested or expected to vest as of March 31, 2023 7,646,307 $ 6.52 7.95 $ 2,037 Options exercisable as of March 31, 2023 3,311,203 $ 6.32 6.65 $ 892
Summary of Assumptions Used to Value Stock Options Granted to Participants Using Black-Scholes Option-Pricing	The fair value of each option award granted is estimated on the date of grant using the Black-Scholes option pric ing model and the weighted average assumptions. The underlying assumptions used to value stock options granted to participants using the Black-Scholes option-pricing presented on a weight average basis were as follows: Three Months Ended March 31, 2023 2022 Risk-free interest rate 3.92 % 1.67 % Expected dividend yield 0 % 0 % Expected option term (in years) range 6.08 6.07 Expected stock price volatility 86.45 83.55

Net Loss per Share Attributab_2

Net Loss per Share Attributable to Common Stockholders (Tables)	3 Months Ended
	Mar. 31, 2023
Earnings Per Share [Abstract]
Summary of Outstanding Potentially Dilutive Securities Excluded in Calculation of Diluted Net Loss Per Share	The following table sets forth the outstanding potentially dilutive securities that have been excluded in the calculation of diluted net loss per share because to do so would be anti-dilutive: Three Months Ended March 31, 2023 2022 Options to purchase Common Stock 7,646,307 6,270,759 Total 7,646,307 6,270,759

Fair Value Measurements - Summa

Fair Value Measurements - Summary of Financial Assets Measured at Fair Value (Details) - Fair Value On Recurring Basis - USD ($) $ in Thousands	Mar. 31, 2023	Dec. 31, 2022
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]
Total assets	$ 134,529	$ 152,889
Level 1
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]
Total assets	11,613	55,861
Level 2
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]
Total assets	122,916	97,028
Money Market Funds
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]
Total Cash Equivalents	11,613	55,861
Money Market Funds | Level 1
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]
Total Cash Equivalents	11,613	55,861
U.S. Treasury Securities
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]
Total Cash Equivalents	10,936
Total Marketable Securities	48,885	22,606
U.S. Treasury Securities | Level 2
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]
Total Cash Equivalents	10,936
Total Marketable Securities	48,885	22,606
Corporate Debt Securities
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]
Total Cash Equivalents	3,496
Total Marketable Securities	59,599	74,422
Corporate Debt Securities | Level 2
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]
Total Cash Equivalents	3,496
Total Marketable Securities	$ 59,599	$ 74,422

Fair Value Measurements - Addit

Fair Value Measurements - Additional Information (Details) - USD ($) $ in Thousands	Mar. 31, 2023	Dec. 31, 2022
Fair Value Disclosures [Abstract]
Fair value, level 3 transfers out, amount	$ 0	$ 0

Marketable securities - Summary

Marketable securities - Summary Of Marketable Securities (Details) - USD ($) $ in Thousands	Mar. 31, 2023	Dec. 31, 2022
Marketable Securities [Line Items]
Amortized Cost	$ 123,407	$ 97,791
Gross Unrealized Gains	5
Gross Unrealized Losses	(496)	(763)
Fair Value	122,916	97,028
U.S. Treasury Securities
Marketable Securities [Line Items]
Amortized Cost	59,845	22,630
Gross Unrealized Gains	4
Gross Unrealized Losses	(28)	(24)
Fair Value	59,821	22,606
Corporate Debt Securities
Marketable Securities [Line Items]
Amortized Cost	63,562	75,161
Gross Unrealized Gains	1
Gross Unrealized Losses	(468)	(739)
Fair Value	$ 63,095	$ 74,422

Marketable Securities - Additio

Marketable Securities - Additional Information (Details)	3 Months Ended
	Mar. 31, 2023 USD ($) Position	Mar. 31, 2022 USD ($)
Investments, Debt and Equity Securities [Abstract]
Number of marketable securities in an unrealized loss position | Position	37
Impairment charges related to available-for-sale securities	$ 0	$ 0
Allowance for credit losses for available for sale debt securities	$ 0	$ 0

Marketable securities - Summa_2

Marketable securities - Summary Of Fair Values Of Marketable Securities (Details) - USD ($) $ in Thousands	Mar. 31, 2023	Dec. 31, 2022
Investments, Debt and Equity Securities [Abstract]
Cash and cash equivalents	$ 14,432
Marketable securities	108,484	$ 97,028
Total	$ 122,916	$ 97,028

Marketable Securities - Schedul

Marketable Securities - Schedule of Marketable Securities Fair Value By Contractual Maturity (Details) - USD ($) $ in Thousands	Mar. 31, 2023	Dec. 31, 2022
Investments, Debt and Equity Securities [Abstract]
Due in one year or less	$ 111,617	$ 79,652
Due after one year through five years	11,299	17,376
Total	$ 122,916	$ 97,028

Prepaid Expenses and Other Cu_3

Prepaid Expenses and Other Current Assets - Summary of Prepaid Expenses and Other Current Assets (Details) - USD ($) $ in Thousands	Mar. 31, 2023	Dec. 31, 2022
Prepaid Expense and Other Assets, Current [Abstract]
Clinical, manufacturing and scientific development	$ 1,862	$ 1,372
Prepaid Insurance	90	727
Other	1,413	964
Total	$ 3,365	$ 3,063

Property and Equipment, Net - S

Property and Equipment, Net - Summary of Property and Equipment (Details) - USD ($) $ in Thousands	Mar. 31, 2023	Dec. 31, 2022
Property and equipment:
Total property and equipment, gross	$ 5,182	$ 5,030
Less: accumulated depreciation	(2,056)	(1,825)
Property and equipment, net	3,126	3,205
Lab Equipment
Property and equipment:
Total property and equipment, gross	3,007	2,858
Leasehold Improvements
Property and equipment:
Total property and equipment, gross	1,219	1,216
Electronic Equipment and Software
Property and equipment:
Total property and equipment, gross	481	481
Furniture and Fixtures
Property and equipment:
Total property and equipment, gross	$ 475	$ 475

Property and Equipment, Net - A

Property and Equipment, Net - Additional Information (Details) - USD ($)	3 Months Ended
	Mar. 31, 2023	Mar. 31, 2022
Property, Plant and Equipment [Abstract]
Depreciation expense	$ 200,000	$ 200,000
Impairment of property and equipment	$ 0	$ 0

Accrued Expenses and Other Cu_3

Accrued Expenses and Other Current Liabilities - Summary of Accrued Expenses and Other Current Liabilities (Details) - USD ($) $ in Thousands	Mar. 31, 2023	Dec. 31, 2022
Accrued Expenses And Other Current Liabilities [Abstract]
Employee compensation	$ 1,128	$ 3,236
Research and development expenses	3,545	4,462
Professional fees	737	526
Other current liabilities	14	119
Total	$ 5,424	$ 8,343

Collaboration Agreement and S_2

Collaboration Agreement and Stock Purchase Agreement with Bristol Myers Squibb - Additional Information (Details) - USD ($) $ in Thousands		3 Months Ended
	Jan. 31, 2019	Mar. 31, 2023	Mar. 31, 2022	Dec. 31, 2022
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
Preferred stock, shares issued		0		0
Deferred revenue current		$ 3,847		$ 9,160
Stock Purchase Agreement with Bristol Myers Squibb | Series A-1 Preferred Stock
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
Preferred stock, shares issued	14,545,450
Bristol Myers Squibb Collaboration Agreement and Stock Purchase Agreement | BMS
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
Upfront consideration payment	$ 95,000
Option to exercise additional consideration if clinical trial not completed within research term	250
Milestone payments eligible to receive	450,000
Bristol Myers Squibb Collaboration Agreement and Stock Purchase Agreement | BMS | IK-175
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
Amount eligible to receive in case of exercise of options	50,000
Bristol Myers Squibb Collaboration Agreement and Stock Purchase Agreement | BMS | IK-412
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
Amount eligible to receive in case of exercise of options	40,000
Bristol Myers Squibb Collaboration Agreement
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
Upfront amount allocated to equity arrangements	1,800
Transaction price allocated to revenue arrangement	78,700
Revenue recognized which were previously included in deferred revenue		5,300	$ 3,400
Deferred revenue		$ 3,800
Bristol Myers Squibb Collaboration Agreement | IK-175
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
Transaction price allocated to revenue arrangement	41,200
Bristol Myers Squibb Collaboration Agreement | IK-412
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
Transaction price allocated to revenue arrangement	$ 37,500

Stock-Based Compensation - Addi

Stock-Based Compensation - Additional Information (Details) - USD ($) $ / shares in Units, $ in Millions		3 Months Ended
	Mar. 30, 2021	Mar. 31, 2023	Mar. 31, 2022	Jan. 01, 2023
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Number of shares reserved for issuance				3,033,386
Weighted-average fair value of the stock options granted		$ 1.96
Total unrecognized stock-based compensation balance for unvested options		$ 17.8
Total unrecognized stock-based compensation balance for unvested options expected to be recognized period		2 years 8 months 12 days
Aggregate intrinsic value of options exercised			$ 0.9
Exercise of stock options, Shares		0
Common Stock
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Exercise of stock options, Shares			134,500
2021 Stock Incentive Plan
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Number of shares reserved for issuance				1,450,299
2021 Employee Stock Purchase Plan
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Plan effective date	Mar. 30, 2021
Increase in number of shares reserved and available for issuance as percentage on common stock outstanding		1%
Number of shares purchased by employees		0
2021 Employee Stock Purchase Plan | Common Stock
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Number of shares issued for purchase		346,613

Stock-Based Compensation - Sche

Stock-Based Compensation - Schedule of Total Compensation Expense (Details) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2023	Mar. 31, 2022
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Total share-based compensation expense	$ 2,000	$ 1,900
Research and Development
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Total share-based compensation expense	1,072	997
General and Administrative
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Total share-based compensation expense	$ 928	$ 903

Stock-Based Compensation - Summ

Stock-Based Compensation - Summary of Stock Option Activity (Details) - USD ($) $ / shares in Units, $ in Thousands	3 Months Ended	12 Months Ended
	Mar. 31, 2023	Dec. 31, 2022
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Number of Options, Exercised	0
2021 Plan
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Number of Options, Outstanding	6,589,479
Number of Options, Granted	1,370,975
Number of Options, Cancelled or forfeited	(314,147)
Number of Options, Outstanding	7,646,307	6,589,479
Number of Options, Vested or expected to vest	7,646,307
Number of Options, Options exercisable	3,311,203
Weighted- Average Exercise Price, Outstanding	$ 7.29
Weighted- Average Exercise Price, Granted	2.63
Weighted- Average Exercise Price, Cancelled or forfeited	5.71
Weighted- Average Exercise Price, Outstanding	6.52	$ 7.29
Weighted- Average Exercise Price, Vested or expected to vest	6.52
Weighted- Average Exercise Price, Options exercisable	$ 6.32
Weighted- Average Remaining Contractual Term, Outstanding	7 years 11 months 12 days	7 years 8 months 23 days
Weighted- Average Remaining Contractual Term, Vested or expected to vest	7 years 11 months 12 days
Weighted- Average Remaining Contractual Term, Option exercisable	6 years 7 months 24 days
Aggregate Intrinsic Value, Outstanding	$ 2,037	$ 362
Aggregate Intrinsic Value, Vested or expected to vest	2,037
Aggregate Intrinsic Value, Options exercisable as of March 31, 2023	$ 892

Stock-Based Compensation - Su_2

Stock-Based Compensation - Summary of Assumptions Used to Value Stock Options Granted to Participants Using Black-Scholes Option-Pricing (Details)	3 Months Ended
	Mar. 31, 2023	Mar. 31, 2022
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Risk-free interest rate	3.92%	1.67%
Expected dividend yield	0%	0%
Expected option term (in years)	6 years 29 days	6 years 25 days
Expected stock price volatility	86.45%	83.55%

Research License Agreements - A

Research License Agreements - Additional Information (Details) - USD ($) $ in Thousands	3 Months Ended	12 Months Ended
	Mar. 31, 2023	Dec. 31, 2018	Dec. 31, 2015
Research And Development Arrangement Contract To Perform For Others [Line Items]
Additional milestone payments payable upon meeting certain development milestones		$ 4,000
UT Austin License | University
Research And Development Arrangement Contract To Perform For Others [Line Items]
License maintenance fees			$ 40
Additional milestone payments payable upon meeting certain development milestones			$ 4,700
Royalties terms	The Company will pay the University royalties as defined in the UT Austin License on any commercialized product sales related to the licensed technology in a percentage in the low single digits.
AskAt License
Research And Development Arrangement Contract To Perform For Others [Line Items]
Royalties terms	The Company will pay the AskAt royalties a percentage in the low single digits as defined in the AskAt License on any commercialized product sales related to the licensed technology.
Total consideration allocated to technology recognized as research and development expense		28,500
AskAt License | Minimum
Research And Development Arrangement Contract To Perform For Others [Line Items]
Milestones payable contingent on sales in calendar year		50,000
AskAt License | Maximum
Research And Development Arrangement Contract To Perform For Others [Line Items]
Milestones payable contingent on sales in calendar year		$ 250,000

Net Loss per Share Attributab_3

Net Loss per Share Attributable to Common Stockholders - Summary of Outstanding Potentially Dilutive Securities Excluded in Calculation of Diluted Net Loss Per Share (Details) - shares	3 Months Ended
	Mar. 31, 2023	Mar. 31, 2022
Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items]
Antidilutive securities excluded from computation of earnings per share amount	7,646,307	6,270,759
Options to Purchase Common Stock
Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items]
Antidilutive securities excluded from computation of earnings per share amount	7,646,307	6,270,759